(Q43097664)

13 November 2017

title

Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients (English)

1 reference

left ventricular hypertrophy

13 November 2017

1 reference

1 reference

1 reference

6

Björn Dahlöf

0 references

Sverre E. Kjeldsen

3

object named as

Sverre E Kjeldsen

1 reference

13 November 2017

7

Richard B Devereux

1 reference

13 November 2017

Peter M Okin

1

1 reference

13 November 2017

Darcy A Hille

2

1 reference

13 November 2017

Lars H Lindholm

4

1 reference

13 November 2017

Jonathan M Edelman

5

1 reference

13 November 2017

publication date

15 April 2010

1 reference

Journal of Clinical Hypertension

13 November 2017

published in

1 reference

13 November 2017

volume

23

1 reference

13 November 2017

issue

7

1 reference

13 November 2017

page(s)

786-793

1 reference

Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Angiotensin increases cytosolic free calcium in cultured vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Independent risk for cardiovascular disease predicted by modified continuous score electrocardiographic criteria for 6-year incidence and regression of left ventricular hypertrophy among clinically disease free men: 16-year follow-up for the multipl

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Left ventricular hypertrophy and clinical outcomes in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS)

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Initial combination therapy compared with monotherapy in diabetic hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Further evidence for low-dose combinations in patients with left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Benazepril combined with either amlodipine or hydrochlorothiazide is more effective than monotherapy for blood pressure control and prevention of end-organ injury in hypertensive Dahl rats

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.65

7 January 2021

Identifiers

DOI

10.1038/AJH.2010.65

1 reference

13 November 2017

1 reference